Previous studies have shown that Saroglitazar (the PPAR α/γ dual agonist used for the treatment of DMT2 and dyslipidemia) produces a significant reduction in lipids and glucose in DT2 patients [14], while Chiglitazar (a PPAR α/γ dual agonist) reduces glucose levels and body weight in animals [15]. The gene discussed is PPARA; the disease is metabolic syndrome.